Skip to main content

Imprint

Information according to §5 DDG:
Okuvision GmbH
Gerhard-Kindler-Str. 17
72770 Reutlingen

Managing Director/CEO: Dr. Alfred Stett

Contact:
Phone: +49 7121 15935 – 0
Fax: +49 7121 15935 – 99
Email: info@okuvision.de

Entry in the Commercial Register.
Local Court Stuttgart HRB 725157
VAT Identification Number: DE258170544

Registration number of the Stiftung Elektro-Altgeräte Register (EAR)
WEEE Reg. No. DE 72437202

Okuvision – Preserving Vision. Protecting Quality of Life.

Okuvision develops innovative therapeutic solutions for people living with retinitis pigmentosa (RP), an inherited retinal disease that can lead to progressive vision loss. With OkuStim®, we offer an evidence-based therapy designed to slow disease progression and help patients preserve their vision for longer. Together with patients, ophthalmologists, and research partners, we are committed to advancing innovative treatment options and improving quality of life.

ContactPartners & Sources of Supply

The OkuStim® therapy was developed for patients with degenerative retinal diseases such as retinitis pigmentosa. It may help slow the progression of the disease. At the core of the therapy is the OkuStim® System, which enables you to stimulate your retina independently at home using low-level electrical currents.

Learn more about Clinical Evidence

Okuvision products are not for sale in the USA.